Artificial intelligence delivers meaningful value in drug development only when it is grounded in real-world constraints and tightly integrated into expert-led workflows, rather than treated as a standalone, model-first solution.
Andrew Lewis, PhD
Advertisement
Andrew Lewis, PhD, is Chief Scientific Officer of Quotient Sciences.
Articles by Andrew Lewis, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
2
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
3
Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors
4
FDA’s ARC Program Highlights Opportunities and Limits of Bayesian Methods in Rare Disease Trials
5